Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells.

Here, we provide the first evidence that sphingosine kinase 1 (SphK1), an oncogenic lipid kinase balancing the intracellular level of key signaling sphingolipids, modulates the transcription factor hypoxia inducible factor 1alpha (HIF-1alpha), master regulator of hypoxia. SphK1 activity is stimulated under low oxygen conditions and regulated by reactive oxygen species. The SphK1-dependent stabilization of HIF-1alpha levels is mediated by the Akt/glycogen synthase kinase-3beta signaling pathway that prevents its von Hippel-Lindau protein-mediated degradation by the proteasome. The pharmacologic and RNA silencing inhibition of SphK1 activity prevents the accumulation of HIF-1alpha and its transcriptional activity in several human cancer cell lineages (prostate, brain, breast, kidney, and lung), suggesting a canonical pathway. Therefore, we propose that SphK1 can act as a master regulator for hypoxia, giving support to its inhibition as a valid strategy to control tumor hypoxia and its molecular consequences.

[1]  Y. Rojanasakul,et al.  Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. , 2007, Cancer research.

[2]  Jonathan Pevsner,et al.  HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.

[3]  P. Mulder,et al.  Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. , 2007, Journal of molecular and cellular cardiology.

[4]  D. Troyer,et al.  Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.

[5]  J. Eisenbart,et al.  Jcb: Article , 2022 .

[6]  D. Gillespie,et al.  Silencing of Hypoxia Inducible Factor-1α by RNA Interference Attenuates Human Glioma Cell Growth In vivo , 2007, Clinical Cancer Research.

[7]  J. Karliner,et al.  Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. , 2007, Cardiovascular research.

[8]  T. Kietzmann,et al.  Glycogen Synthase Kinase 3 Phosphorylates Hypoxia-Inducible Factor 1α and Mediates Its Destabilization in a VHL-Independent Manner , 2007, Molecular and Cellular Biology.

[9]  O. Cuvillier.  Sphingosine kinase-1 – a potential therapeutic target in cancer , 2007, Anti-cancer drugs.

[10]  O. Kunduzova,et al.  Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis , 2007, Circulation research.

[11]  S. Hahn,et al.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. , 2006, Cancer research.

[12]  S. Pyne,et al.  The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. , 2006, Prostaglandins & other lipid mediators.

[13]  M. Golzio,et al.  Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. , 2005, Cancer research.

[14]  Thomas W Prior,et al.  Sphingosine Kinase-1 Expression Correlates With Poor Survival of Patients With Glioblastoma Multiforme: Roles of Sphingosine Kinase Isoforms in Growth of Glioblastoma Cell Lines , 2005, Journal of neuropathology and experimental neurology.

[15]  P. Schumacker,et al.  Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. , 2005, Cell metabolism.

[16]  Massimo Zeviani,et al.  Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. , 2005, Cell metabolism.

[17]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[18]  E. Goetzl,et al.  Sphingosine Kinase Activation Mediates Ischemic Preconditioning in Murine Heart , 2004, Circulation.

[19]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Christopher J. Schofield,et al.  Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.

[21]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[22]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[23]  Brian D. Lee,et al.  Discovery and evaluation of inhibitors of human sphingosine kinase. , 2003, Cancer research.

[24]  D. Mottet,et al.  Regulation of Hypoxia-inducible Factor-1α Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Pathway in HepG2 Cells* , 2003, Journal of Biological Chemistry.

[25]  Sarah Spiegel,et al.  Sphingosine-1-phosphate: an enigmatic signalling lipid , 2003, Nature Reviews Molecular Cell Biology.

[26]  M. Kester,et al.  Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. , 2002, Archives of biochemistry and biophysics.

[27]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[28]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[29]  J. Gutkind,et al.  MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. , 2001, Biochemical and biophysical research communications.

[30]  G. Semenza,et al.  Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1* , 2001, The Journal of Biological Chemistry.

[31]  J. Simons,et al.  Angiogenesis and prostate cancer: identification of a molecular progression switch. , 2001, Cancer research.

[32]  A. Giaccia,et al.  Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. , 2001, Cancer research.

[33]  J. Gamble,et al.  An oncogenic role of sphingosine kinase , 2000, Current Biology.

[34]  N. Chandel,et al.  Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1α during Hypoxia , 2000, The Journal of Biological Chemistry.

[35]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[36]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[37]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[38]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[39]  M. Ittmann,et al.  Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. , 1999, Human pathology.

[40]  N. Chandel,et al.  Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Giaccia,et al.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.

[42]  S. Spiegel,et al.  Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate , 1996, Nature.

[43]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[44]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[46]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[47]  E. Cohen-Jonathan-Moyal,et al.  Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. , 2006, Cancer research.

[48]  G. Semenza,et al.  Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.

[49]  D Beitner-Johnson,et al.  Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. , 2001, Cellular signalling.

[50]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.